Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439985 | 0.79 | PDE10A (0.39) | PDE10A | |
| SCHEMBL29018914 | 0.77 | IDO1 (0.39) | PDE10ALMNAIDO1 | |
| SCHEMBL26608186 | 0.76 | LMNA (0.36) | LMNA | |
| SCHEMBL31336324 | 0.76 | LMNA (0.36) | LMNA | |
| SCHEMBL13035870 | 0.76 | LMNA (0.41) | PDE10ALMNAIDO1 | |
| SCHEMBL7759535 | 0.73 | PDE10A (0.39) | PDE10ALMNA | |
| SCHEMBL801870 | 0.71 | ALDH1A1 (0.39) | PDE10A | |
| SCHEMBL1830615 | 0.71 | PDE10A (0.37) | PDE10ALMNA | |
| SCHEMBL24843578 | 0.70 | GAA (0.36) | PDE10ALMNAIDO1 | |
| SCHEMBL4314460 | 0.70 | TDP1 (0.35) | PDE10ALMNAIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118566353-A | Method for detecting genotoxic impurities in omeprazole and preparation thereof | 康普药业股份有限公司 | 2024-08-30 | — | — | CN | claimed |
| EP-0226558-B1 | Chemical intermediates and methods for their preparation | HAESSLE AB (SE) | 1994-04-06 | — | — | EP | claimed |
| EP-0226558-A2 | Chemical intermediates and methods for their preparation | Aktiebolaget Hässle (SE) | 1987-06-24 | — | — | EP | claimed |
| CN-118566353-A | Method for detecting genotoxic impurities in omeprazole and preparation thereof | 康普药业股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-118566353-A | Method for detecting genotoxic impurities in omeprazole and preparation thereof | 康普药业股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-114044752-A | Production method of omeprazole drug intermediate 2-chloromethyl-3, 5-dimethyl-4-methoxypyridine hydrochloride | 上海卓鼎生物技术有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-8841331-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130203747-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-8338441-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| EP-0226558-B1 | Chemical intermediates and methods for their preparation | HAESSLE AB (SE) | 1994-04-06 | — | — | EP | disclosed |
| EP-0369208-B1 | PROCESS FOR THE PREPARATION OF 3,5-DIMETHYL-4-METHOXY PYRIDINE DERIVATIVES, AND INTERMEDIATE THEREFOR | Hafslund Nycomed Pharma Aktiengesellschaft (AT) | 1993-03-17 | — | — | EP | disclosed |
| US-5066810-A | 3,5-DIMETHYL-4-METHOXYPYRIDINE DERIVATIVES | CL PHARMA AKTIENGESELLSCHAFT (AT) | 1991-11-19 | — | — | US | disclosed |
| EP-0369208-A1 | Process for the preparation of 3,5-dimethyl-4-methoxy pyridine derivatives, and intermediate therefor | Hafslund Nycomed Pharma Aktiengesellschaft (AT) | 1990-05-23 | — | — | EP | disclosed |
| US-4785113-A | 2,4-dichloro-3,5,6-trimethylpyridine | AKTIEBOLAGET HASSLE (SE) | 1988-11-15 | — | — | US | disclosed |
| US-4785113-A | 2,4-dichloro-3,5,6-trimethylpyridine | AKTIEBOLAGET HASSLE (SE) | 1988-11-15 | — | — | US | disclosed |
| EP-0226558-A2 | Chemical intermediates and methods for their preparation | Aktiebolaget Hässle (SE) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | PDE10A 4187/4885LMNA 4178/4885IDO1 463/4885 |
| US-20130203747-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | PDE10A 4187/4885LMNA 4178/4885IDO1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.